Open Access Peer-reviewed Hypothesis

Effects of Pinus massoniana bark extract on the size of HeLa cells via Nesprin-2 pathway

Main Article Content

Xiaolu Zhang
Mengqi Li
Yingya Li
Jiao Feng
Yingyu Cui corresponding author


Proanthocyanidins (PAs) is the main constituent of Pinus massoniana bark extract (PMBE). PMBE was reported to induce cell cycle arrest and apoptosis in HeLa cells. During cell division, cells synthesize protein in G1 and G2 phases and replicate chromatin in S phase during interphase, which increases cell mass. Nesprins, a kind of protein encoded by syne gene, is a vital part of cytoskeleton and plays a role in cell cycle progress and cell division. HeLa cells were used as a model to examine effects of PMBE on cell growth and Nesprins expression with MTT assay and RT- PCR analysis, respectively. The cell size was evaluated by counting the cell number in a fixed area under microscope. The results showed that the size of survival HeLa cells in PMBE-treated group was obviously larger than that of those in control group (p = 0.00223, < 0.01), while the mRNA expression level of Nesprin-2 decreased significantly in PMBE-treated group (p = 0.0201, < 0.05). On this account, we put forward a hypothesis that PMBE inhibits the expression of syne-2, which leads to the decrease of Nesprin-2 and further results in the size increase of HeLa cells.

Proanthocyanidins (PAs), Pinus massoniana bark extract (PMBE), Cell size, HeLa cells, Nesprins

Article Details

Supporting Agencies
This project was funded by National University Students Innovation Training Program, grant number: 1500107070; Yangfan Project of Tongji University School of Medicine, grant number: 2012YF05; Fundamental Research Funds for the Central Universities, grant number: 22120180190 and Shanghai Educational Research Project grant number: C19154.
How to Cite
Zhang, X., Li, M., Li, Y., Feng, J., & Cui, Y. (2020). Effects of Pinus massoniana bark extract on the size of HeLa cells via Nesprin-2 pathway. Current Cancer Reports, 2(1), 41-47.


  1. Cui YY, Xie H andWang JF. Potential biomedical properties of Pinus massoniana bark extract. Phytotherapy Research, 2005, 19(1): 34-38.
  2. Cui YY, Xie H, Qi KB, et al. Effects of Pinus massoniana bark extract on cell proliferation and apoptosis of human hepatoma BEL-7402 cells. World Journal of Gastroenterology, 2005, 11(34): 5277-5282.
  3. Yang ZQ, Chen H, Tan JH, et al. Cloning of three genes involved in the flavonoid metabolic pathway and their expression during insect resistance in Pinus massoniana Lamb. Ge-netics & Molecular Research, 2016, 15(4): gmr15049332.
  4. Zeng YX,Wang S,Wei L, et al. Proanthocyanidins: Components, Pharmacokinetics and Biomedical Properties. American Journal of Chinese Medicine, 2020, 48(4): 813-869.
  5. Wu CL, Feng DR, Ma HL, et al. Effect of Pinus massoniana bark extract on IFN- -induced ICAM-1 expression in Ha- CaT human keratinocytes. Journal of Ethnopharmacology, 2009, 122 (1): 48-53.
  6. Feng J, Zhang XL, Li YY, et al. Pinus massoniana Bark Extract: Structure-Activity Relationship and Biomedical Potentials. The American Journal of Chinese Medicine, 2016, 44(8): 1559-1577.
  7. Xu S, Zhang S, Wang X, et al. Effect of Pinus massoniana Lamb. bark extract on lytic cycle of Epstein-Barr virus. Indian Journal of Experimental Biology, 2012, 50(10): 708- 713.
  8. Mao P, Zhang E, Chen Y, et al. Pinus massoniana bark extract inhibits migration of the lung cancer A549 cell line. Oncology Letters, 2017, 13(2): 1019-1023.
  9. Ma H, Liu B, Feng D, et al. Pinus massoniana bark extract selectively induces apoptosis in human hepatoma cells, possibly through caspase-dependent pathways. International Journal of Molecular Medicine, 2010, 25(5): 751-759.
  10. Li YY, Feng J, Zhang XL, et al. Pine bark extracts: nutraceutical, pharmacological, and toxicological evaluation. Journal of Pharmacology & Experimental Therapeutics, 2015, 353(1): 9-16.
  11. Lin BW, Gong CC, Song HF, et al. Effects of anthocyanins on the prevention and treatment of cancer. British Journal of Pharmacology, 2017, 174(11): 1226-1243.
  12. Wu DC, Li S, Yang DQ, et al. Effects of Pinus massoniana bark extract on the adhesion and migration capabilities of HeLa cells. Fitoterapia, 2011, 82(8): 1202-1205.
  13. Li YY, Feng J, Zhang XL, et al. Effects of Pinus massoniana bark extract on the invasion capability of HeLa cells. Journal of Functional Foods, 2016, 24: 520-526.
  14. Zhao CX, Cui YY and Chen YH. Progress of The Research on Nesprins. Progress in Biochemistry and Biophysics, 2014, 41(4): 337-344. pdf.aspx?fil e no=20130186&flag=1&journal id=pibbcn
  15. Zhou C, Rao L, Shanahan CM, et al. Nesprin-1/2: roles in nuclear envelope organisation, myogenesis and muscle disease. Biochemical Society Transactions, 2018, 46(2): 311- 320.
  16. Elvira I, Alessia C, Robin F, et al. LINC complex-Lis1 interplay controls MT1-MMP matrix digest-on-demand response for confined tumor cell migration. Nature Communications, 2018, 9(1): 1-13.
  17. King SJ, Nowak K, Suryavanshi N, et al. Nesprin-1 and nesprin-2 regulate endothelial cell shape and migration. Cytoskeleton, 2014, 71(7): 423-434.
  18. Matsumoto A, Hieda M, Yokoyama Y, et al. Global loss of a nuclear lamina component, lamin A/C, and LINC complex components SUN1, SUN2, and nesprin-2 in breast cancer. Cancer Medicine, 2015, 4(10): 1547-1557.
  19. Schneider M, Lu W, Neumann S, et al. Molecular mechanisms of centrosome and cytoskeleton anchorage at the nuclear envelope. Cellular & Molecular Life Sciences Cmls, 2011, 68(9): 1593-1610.
  20. Bj¨orklund M. Cell size homeostasis: Metabolic control of growth and cell division. Biochimica Et Biophysica Acta Molecular Cell Research, 2019, 1866(3): 409-417.
  21. Ginzberg MB, Kafri R and Kirschner M. On being the right (cell) size. Science, 2015, 348(6236): 771.
  22. Dungrawala H, Hua H, Wright J, et al. Identification of new cell size control genes in S. cerevisiae. Cell Division, 2012, 7(24): 1-13.
  23. Horbay R, Boiko N, Shlyakhtina Y, et al. Giant cancer cells: overcoming drug resistance again and again. Total overview, 2012.
  24. Montgomery C, Couch C, Emory CL, et al. Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. Journal of Knee Surgery, 2019, 32(4): 331-336.
  25. Amend SR, Torga G, Lin KC, et al. Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance. Prostate, 2019, 79(13): 1489-1497.
  26. Vitale I, Jema`a M, Senovilla L, et al. Involvement of p38alpha in the mitotic progression of p53(-/-) tetraploid cells. Cell Cycle, 2010, 9(14): 2823-2829.
  27. Yeung YT, Yin S, Lu B, et al. Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization. EBioMedicine, 2018, 28: 51-61.
  28. Fan P, Li HX, Wu YM, et al. Biological characteristics of paclitaxel-resistance ovarian cancer cell lines and cryopreservation methods. Cancer Research on Prevention and Treatment, 2015, 42(4): 334-339.
  29. Liu X, Jia YH, Zhang K, et al. Establishment of crizotinibresistant non-small cell lung cancer cell line NCI-H3122and preliminary study of resistance related miRNAs. Journal of Third Military Medical University, 2016, 38(7): 687- 692.
  30. Yvorel V, Patoir A, Casteillo F, et al. PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. PLoS One, 2017, 12(7): e0180346.
  31. Du JP, Chen P, Fei HX, et al. Establishment of adriamycinresistant and cisplatin-resistant gastric cancer cell lines and assessment on their sustainability of drug resistance. Journal of Gastroenterology and Hepatology, 2007, 16(4): 368-372.
  32. Gul A, Leylandjones B, Dey N, et al. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. American Journal of Cancer Research, 2018, 8(12): 2359-2376.
  33. Wang Y, Yuan BB and Yue TF. Research progress of polyploidy and cancer. Journal of International Obstetrics and Gynecology, 2010, 37(6): 420-426. (In Chinese)
  34. Cui YY. Cancer, mankind’s challenge. Current Cancer Reports, 2019, 1(1): 1-5.
  35. Robert G and Christopher W. Cancer treatment innovators discover Charles Darwin. Evolution, Medicine, and Public Health, 2019, 2019(1): 108-110.
  36. DeGregori J and Gatenby R. Darwin’s ideas on evolution drive a radical new approach to cancer drug use. Principle of evolution and natural selection drive a radical new approach to drugs and prevention strategies. Scientific American, 2019, 321(2): 52.